Hong Kong
· Delayed Price · Currency is HKD QuantumPharm Statistics
Total Valuation
QuantumPharm has a market cap or net worth of HKD 13.90 billion. The enterprise value is 10.46 billion.
| Market Cap | 13.90B |
| Enterprise Value | 10.46B |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QuantumPharm has 3.41 billion shares outstanding. The number of shares has increased by 25.77% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.41B |
| Shares Change (YoY) | +25.77% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.48% |
| Float | 1.48B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.69 |
| PB Ratio | 0.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.84 |
| EV / Sales | 49.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.30 |
Financial Position
The company has a current ratio of 15.68, with a Debt / Equity ratio of 0.04.
| Current Ratio | 15.68 |
| Quick Ratio | 15.44 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.24 |
| Interest Coverage | -84.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 278,638 |
| Profits Per Employee | -3.59M |
| Employee Count | 783 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 9.46 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 25.80 |
| Average Volume (20 Days) | 28,035,174 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, QuantumPharm had revenue of HKD 211.77 million and -2.73 billion in losses. Loss per share was -4.50.
| Revenue | 211.77M |
| Gross Profit | 99.16M |
| Operating Income | -859.20M |
| Pretax Income | -2.71B |
| Net Income | -2.73B |
| EBITDA | -770.85M |
| EBIT | -859.20M |
| Loss Per Share | -4.50 |
Balance Sheet
The company has 3.64 billion in cash and 175.76 million in debt, giving a net cash position of 3.46 billion or 1.02 per share.
| Cash & Cash Equivalents | 3.64B |
| Total Debt | 175.76M |
| Net Cash | 3.46B |
| Net Cash Per Share | 1.02 |
| Equity (Book Value) | 4.45B |
| Book Value Per Share | 6.07 |
| Working Capital | 3.53B |
Cash Flow
In the last 12 months, operating cash flow was -610.17 million and capital expenditures -121.56 million, giving a free cash flow of -731.73 million.
| Operating Cash Flow | -610.17M |
| Capital Expenditures | -121.56M |
| Free Cash Flow | -731.73M |
| FCF Per Share | -0.21 |
Margins
| Gross Margin | 46.83% |
| Operating Margin | -405.73% |
| Pretax Margin | -1,280.46% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -345.54% |
Dividends & Yields
QuantumPharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.77% |
| Shareholder Yield | -25.77% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
QuantumPharm has an Altman Z-Score of 29.52.
| Altman Z-Score | 29.52 |
| Piotroski F-Score | n/a |